Significance of maximal and regional left ventricular wall thickness in association with arrhythmic events in patients with hypertrophic cardiomyopathy

Circulation Journal

Volumn 74, Issue 3, 2010, Pages 531-537

  Puntmann, Valentina O ^a   Yap, Yee Guan ^a   McKenna, William ^b   Camm, A John ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Hypertrophic cardiomyopathy; Left ventricular wall thickness; Ventricular tachyarrhythmias

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE WALL; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALIDITY; RISK FACTOR; RISK MANAGEMENT; SUDDEN DEATH; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

ADULT; CARDIOMYOPATHY, HYPERTROPHIC; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY, AMBULATORY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TACHYCARDIA, VENTRICULAR; YOUNG ADULT;

EID: 77649209473     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-09-0723     Document Type: Article

References (42)

1. Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003; 41: 315-321.
2. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000; 342: 1778-1785.
3. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: A position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2008; 29: 270-276.
4. Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000; 355: 58-60.
5. Maron BJ, Epstein SE. Hypertrophic cardiomyopathy: Recent observations regarding the specificity of three hallmarks of the disease: Asymmetric septal hypertrophy, septal disorganization and systolic anterior motion of the anterior mitral leaflet. Am J Cardiol 1980; 45: 141-154.
6. Wigle ED, Sasson Z, Henderson MA, Ruddy TD, Fulop J, Rakowski H, et al. Hypertrophic cardiomyopathy: The importance of the site and the extent of hypertrophy: A review. Prog Cardiovasc Dis 1985; 28: 1-83.
7. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A two-dimensional echocardiographic study. J Am Coll Cardiol 1983; 2: 437-444.
8. Kimura A. Molecular etiology and pathogenesis of hereditary cardiomyopathy. Circ J 2008; 72(Suppl A): A-38-A-48.
9. Cheitlin MD, Armstrong WF, Aurigemma GP, Beller GA, Bierman FZ, Davis JL, et al. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee Update the 1997 Guidelines on the Clinical Application of Echocardiography). Circulation 2003; 108: 1146-1162.
10. Gardin JM, Adams DB, Douglas PS, Feigenbaum H, Forst DH, Fraser AG, et al, American Society of Echocardiography. Recommendations for a standardized report for adult transthoracic echocardiography: A report from the American Society of Echocardiography's Nomenclature and Standards Committee and Task Force for a Standardized Echocardiography Report. J Am Soc Echocardiogr 2002; 15: 275-290.
11. Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. Heart 2006; 92: 785-791.
12. Sen-Chowdhry S, McKenna WJ. Non-invasive risk stratification in hypertrophic cardiomyopathy: Don't throw out the baby with the bathwater. Eur Heart J 2008; 29: 1600-1602.
13. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990; 82: 1995-2002.
14. Schumacher B, Gietzen FH, Neuser H, Schümmelfeder J, Schneider M, Kerber S, et al. Electrophysiological characteristics of septal hypertrophy in patients with hypertrophic obstructive cardiomyopathy and moderate to severe symptoms. Circulation 2005; 112: 2096-2101.
15. Saumarez RC, Pytkowski M, Sterlinski M, Bourke JP, Clague JR, Cobbe SM, et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 2008; 29: 1653-1661.
16. Kofflard MJ, Ten Cate FJ, van der Lee C, van Domburg RT. Hypertrophic cardiomyopathy in a large community-based population: Clinical outcome and identification of risk factors for sudden cardiac death and clinical deterioration. J Am Coll Cardiol 2003; 41: 987-993.
17. McKenna WJ, England D, Doi YL, Deanfield JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis. Br Heart J 1981; 46: 168-172.
18. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24-hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. Am J Cardiol 1981; 48: 252-257.
19. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: Assessment in an unselected non-referral based patient population. Heart 1998; 79: 331-336.
20. Spirito P, Rapezzi C, Autore C, Bruzzi P, Bellone P, Ortolani P, et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 1994; 90: 2743-2747.
21. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. J Am Coll Cardiol 2003; 42: 873-879.
22. Olivotto I, Maron MS, Adabag AS, Casey SA, Vargiu D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 46: 480-487.
23. Varnava AM, Elliott PM, Sharma S, McKenna WJ, Davies MJ. Hypertrophic cardiomyopathy: The interrelation of disarray, fibrosis, and small vessel disease. Heart 2000; 84: 476-482.
24. McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988; 11: 147-153.
25. Fananapazir I, Tracy CM, Leon MB, Cannon RO III, Bonow RO, Maron BJ, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy: A consecutive analysis in 155 patients. Circulation 1989; 80: 1259-1268.
26. Stewart JT, McKenna WJ. Arrhythmias in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 1991; 2: 516-524.
27. Saumarez RC, Camm AJ, Panagos A, Gill JS, Stewart JT, DeBelder MA, et al. Ventricular fibrillation in hypertrophic cardiomyopathy is associated with increased fractionation of paced right ventricular electrograms. Circulation 1992; 86: 467-474.
28. Kim RJ, Judd R. Gadolinium-enhanced magnetic resonance imaging in hypertrophic cardiomyopathy: In vivo imaging of the pathologic substrate for premature cardiac death? J Am Coll Cardiol 2003; 41: 1568-1572.
29. Teraoka K, Hirano M, Ookubo H, Sasaki K, Katsuyama H, Amino M, et al. Delayed contrast enhancement of MRI in hypertrophic cardiomyopathy. Magn Reson Imaging 2004; 22: 155-161.
30. Nagai T, Kurita T, Satomi K, Noda T, Okamura H, Shimizu W, et al. QRS prolongation is associated with high defibrillation thresholds during cardioverter-defibrillator implantations in patients with hypertrophic cardiomyopathy. Circ J 2009; 73: 1028-1033.
31. Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol 2003; 41: 1561-1567.
32. Adabag AS, Casey SA, Kuskowski MA, Zenovich AG, Maron BJ. Spectrum and prognostic significance of arrhythmias on ambulatory Holter electrocardiogram in hypertrophic cardiomyopathy. J Am Coll Cardiol 2005; 45: 697-704.
33. Matsuo S, Nakamura Y, Takahashi M, Mitsunami K, Kinoshita M. Myocardial metabolic abnormalities in hypertrophic cardiomyopathy assessed by iodine-123-labeled beta-methyl-branched fatty acid myocardial scintigraphy and its relation to exercise-induced ischemia. Jpn Circ J 1998; 62: 167-172.
34. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003; 349: 1027-1035.
35. Knaapen P, van Dockum WG, Bondarenko O, Kok WE, Götte MJ, Boellaard R, et al. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: Comparison between CMR and PET. J Nucl Med 2005; 46: 923-929.
36. Knaapen P, van Dockum WG, Götte MJ, Broeze KA, Kuijer JP, Zwanenburg JJ, et al. Regional heterogeneity of resting perfusion in hypertrophic cardiomyopathy is related to delayed contrast enhancement but not to systolic function: A PET and MRI study. J Nucl Cardiol 2006; 13: 660-667.
37. Choudhury L, Mahrholdt H, Wagner A, Choi KM, Elliott MD, Klocke FJ, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40: 2156-2164.
38. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003; 348: 295-303.
39. Autore C, Bernarbo P, Barilla CS, Bruzzi P, Spirito P. The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms. J Am Coll Cardiol 2005; 45: 1076-1080.
40. Ozaki K, Sakuma I, Mitsuma K, Suzuki T, Tsuchida K, Takahashi K, et al. Effect of cibenzoline and atenolol administration on dynamic left ventricular obstruction due to sigmoid-shaped septum. Circ J 2008; 72: 2087-2091.
41. Elliott P, Gimeno J, Tomé M, McKenna W. Left ventricular out-flow tract obstruction and sudden death in hypertrophic cardiomyopathy. Eur Heart J 2006; 27: 1933-1941.
42. Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: From idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol 2009; 54: 191-200.